Segall Bryant & Hamill LLC Sells 12,044 Shares of Guardant Health, Inc. $GH

Segall Bryant & Hamill LLC lowered its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 4.9% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 232,222 shares of the company’s stock after selling 12,044 shares during the period. Segall Bryant & Hamill LLC’s holdings in Guardant Health were worth $21,450,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. V Square Quantitative Management LLC purchased a new position in Guardant Health in the fourth quarter worth $27,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Guardant Health during the fourth quarter valued at about $31,000. Elyxium Wealth LLC purchased a new stake in Guardant Health during the fourth quarter valued at about $35,000. Parallel Advisors LLC lifted its stake in Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares during the last quarter. Finally, Ascentis Independent Advisors bought a new stake in Guardant Health during the first quarter worth about $38,000. 92.60% of the stock is owned by institutional investors.

Key Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Revenue and testing growth exceeded expectations. Second-quarter revenue rose 44% year over year to $335.0 million, above the $314.2 million analyst estimate. Oncology revenue increased 38% to $219.1 million, while oncology test volume climbed 63% to approximately 104,000. Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: Guardant raised its 2026 revenue guidance to $1.3 billion-$1.4 billion, compared with consensus around $1.3 billion. The outlook increase signals continued demand for the company’s cancer-screening and precision-oncology tests. Guardant Health hits 52-week high after guidance hike
• Positive Sentiment: JPMorgan raised its price target from $185 to $195 and maintained an “overweight” rating, reinforcing bullish analyst sentiment and suggesting additional potential upside. JPMorgan raises Guardant Health price target
• Neutral Sentiment: Guardant reported a second-quarter adjusted loss of $0.42 per share, compared with a $0.44 loss a year earlier. Reports differed on the consensus comparison, with one estimate showing a modest miss and another indicating a substantial beat. Guardant Health Q2 earnings report
• Negative Sentiment: Profitability remains a concern. Guardant continues to generate quarterly losses, and investor commentary is weighing whether rapidly rising revenue can offset ongoing spending and losses. Does Guardant’s Surging Revenue and Deeper Losses Reframe the Growth Thesis for GH?

Insider Transactions at Guardant Health

In other Guardant Health news, CEO Helmy Eltoukhy sold 100,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $126.30, for a total value of $12,630,000.00. Following the completion of the sale, the chief executive officer owned 2,012,919 shares in the company, valued at approximately $254,231,669.70. The trade was a 4.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Chris Freeman sold 24,406 shares of the stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $118.67, for a total value of $2,896,260.02. Following the sale, the insider directly owned 60,034 shares of the company’s stock, valued at approximately $7,124,234.78. This trade represents a 28.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 708,565 shares of company stock valued at $90,556,597. 5.60% of the stock is currently owned by corporate insiders.

Guardant Health Stock Up 6.3%

NASDAQ GH opened at $161.99 on Friday. The company has a 50-day simple moving average of $143.44 and a two-hundred day simple moving average of $113.38. Guardant Health, Inc. has a 12-month low of $40.35 and a 12-month high of $176.58. The firm has a market cap of $21.48 billion, a price-to-earnings ratio of -46.42 and a beta of 1.59.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on GH. Piper Sandler set a $127.00 price objective on Guardant Health in a report on Thursday, May 21st. Royal Bank Of Canada boosted their target price on Guardant Health from $185.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday. Sanford C. Bernstein upped their target price on Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, July 2nd. TD Cowen upped their target price on Guardant Health from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Friday. Finally, JPMorgan Chase & Co. increased their price target on shares of Guardant Health from $185.00 to $195.00 and gave the company an “overweight” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Guardant Health has a consensus rating of “Moderate Buy” and a consensus target price of $179.82.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.